Inhalation and Nasal Spray Generic Drugs Market Size, Share and Trends 2024 to 2034

Inhalation and Nasal Spray Generic Drugs Market Size and Forecast 2024 to 2034

The global inhalation and nasal spray generic drugs market size is projected to surpass around USD 54.44 billion by 2034 from USD 23.06 billion in 2024, at a CAGR of 8.97% between 2024 and 2034. The North America interleukin inhibitors market size reached USD 8.04 billion in 2023. The rising cases of chronic respiratory illness worldwide are driving the growth of the market.

Inhalation and Nasal Spray Generic Drugs Market Key Takeaways

• North America dominated the inhalation and nasal spray generic drugs market with the largest market share of 38% in 2023.
• Asia Pacific is expected to grow at a double digit CAGR of 11.25% during the forecast period.
• By drug class, the bronchodilators segment has recorded more than 27% of market share in 2023.
• By drug class, the combination drugs segment is projected to grow at a solid CAGR of 9.86% during the forecast period.
• By patient demographics, the adult patient segment contributed more than 42% of market share in 2023.
• By patient demographics, the pediatric patient segment is expected to expand at a notable CAGR during the forecast period.
• By indication, the asthma segment accounted for the largest market share of 43% in 2023.
• By indication, the chronic obstructive pulmonary disease (COPD) segment is expecting notable growth during the anticipated period.
• By end-user, the homecare segment generated more than 53% of market share in 2023.
• By distribution channel, the retail pharmacies segment accounted for the highest market share of 57% in 2023.
• By distribution channel, the online pharmacies segment is expected to hold a significant share during the forecast period.

U.S. Inhalation and Nasal Spray Generic Drugs Market Size and Growth 2024 to 2034

The U.S. inhalation and nasal spray generic drugs market size was exhibited at USD 6.03 billion in 2023 and is projected to be worth around USD 15.82 billion by 2034, poised to grow at a CAGR of 9.16% from 2024 to 2034.

North America dominated the market with the largest inhalation and nasal spray generic drugs market share in 2023. The growth of the market in the region is attributed to the rising number of patients with asthma and COPD in the adult and pediatric population, which boosts the demand for treatment procedures and drives the growth of the inhalation and nasal spray generic drug market in the region.

Asia Pacific is expected to grow significantly during the forecast period. The growth of the market is attributed to the rising regional population in countries like India and China and the increasing cases of breathing-related issues due to the aging factors in the population and the acceptance of unhealthy lifestyles like the higher prevalence of smoking by the population and the rising air pollution due to the rising carbon emission by the vehicles and the pollution by the industries that results in the negative impacts in the human body and causes the number of lung disease that boosts the growth of the inhalation and nasal spray generic drugs market in the region.

• According to GlobalData's Clinical Trials Database, 51.8% of asthma trials were started in the APAC region. China led the way with 337 asthma clinical trials within the APAC region from 1019 to 2023. India followed with 197 trials, and South Korea with 83 trials.

Market Overview

The inhalation and nasal spray generic drugs are the treatment or the medication drug that is used to treat the breathing disease in humans. The nasal spray includes therapeutic active ingredients. These active ingredients dissolve in the solution in a non-pressurized dispenser that delivers the drug by spraying in the metered or quantified dosage. Furthermore, the inhalation solution is a liquid-based solution that contains active ingredients and additional excipients. The rising cases of asthma and chronic obstructive pulmonary disease (COPD) in the population are driving the growth of the inhalation and nasal spray generic drugs market.

How can AI Help the Inhalation and Nasal Spray Generic Drugs Market?

The integration of artificial intelligence in healthcare and pharmaceutical operations, such as drug formulation and drug development, revolutionized the healthcare industry. AI could help revolutionize the operations of the pharmaceutical industry by enhancing productivity and the formulation of drugs. AI helps in improving the treatment of COPD; it helps in the analysis of CT imaging of patients with COPD and predicts the overall risk and further treatment procedures for patients as per the condition of the patient's CT imaging.

AI helps in predicting and informing the prognosis and progression of chronic obstructive pulmonary disease (COPD). AI could help the conditions of chronic respiratory disease in several ways by predicting the ongoing and future condition of the diseases and helps the physicians by providing real-time insights about the patient’s condition that helps physician to prescribe the medication to the patients.

• In June 2024, Intermountain Health extended its collaboration with CareCentra, Inc., including remote monitoring for chronic obstructive pulmonary disease (COPD) patients and asthma to detect symptoms exacerbation and intervene earlier.

Inhalation and Nasal Spray Generic Drugs Market Growth Factors

• The increasing cases of breathing-related issues or diseases in the population by the various genetic, environmental conditions, and allergies that result in the number of diseases such as asthma and chronic obstructive pulmonary diseases (COPD) that drive the growth of the market.
• The rising prevalence of asthma, COPD, and other instant breathing-related diseases drives the demand for treatment medication, which drives the demand for the inhalation and nasal spray generic drugs market.
• The rising inclination towards home care and remote treatment for various diseases, driven by the rise in the geriatric population and the advancement of telehealth, is one of the leading factors driving the growth of the market.
• The increasing demand for instant and long-term relief from the different types of breathing issues such as asthma, COPD, or unexpected breathlessness is driving the growth of the Inhalation and nasal spray generic drugs market.
• The rising advancement in the treatment of lung diseases such as asthma and other diseases, with the rising investment in drug and treatment development and launch of further drugs, are driving the growth of the market.

Market Scope

Market Dynamics

Driver

Increasing environmental pollution and other factors that are contributing in the growth of the inhalation and nasal spray generic drugs market

The rising global warming, air pollution due to the growing number of vehicles, the rising carbon emissions from vehicles, and the increasing number of industrial pollution are severely impacting the health of humans. Environmental pollution is one of the leading causes of chronic respiratory diseases and other breathing issues in the population that drives the demand for treatment and medication that will be conveniently adopted by patients with conditions that will highly contribute to the growth of the inhalation and nasal spray generic drugs market.

Restraint

Stringent regulation for the generic medication

There are several stringent regulations in the adoption of generic drugs that are restraining the growth of the generic drugs inhalation and nasal spray market.

Opportunity

Government support for the production of drugs

The rising government investment the public and private market investment in the development and launch of the drugs, and the major pharmaceutical firms investing in the innovation in the treatment and medication of respiratory disease are fueling the growth of the market. The increasing government initiative and supporting regulations in the development of the healthcare and pharmaceutical sector are driving the opportunity in the growth of the inhalation and nasal spray generic drugs market.

Drug Class Insights

The bronchodilators segment occupied the highest market share of 27% in 2023.

The growth of the segment is attributed to the rising prevalence of asthma and other lung-related diseases, which are driving the growth of the bronchodilators drug. Bronchodilators are used as a medication for diseases related to breathing or lung problems. It relaxes the muscles in the lungs and wide the airways. It is used in the treatment of asthma, a very common lung condition that is a major cause of inflammation of the airways.

The bronchodilators are also used in chronic obstructive pulmonary disease (COPD); the major cause of this condition is smoking, which is the group of lung disease infection that makes breathing difficult. The bronchodilator drug is used both as a long-term medication and short-term medication. Long-term medication is used for conditions like asthma and COPD, and short-term medication is used for unexpected attacks like breathlessness.

The combination drugs segment is expected to show the fastest CAGR of 9.86% during the forecast period. The rising use of combination drugs is due to the rise in chronic obstructive pulmonary diseases and asthma. It is the type of medication that includes one or two drugs in a single dosage form at a fixed dose.

Patient Demographics Insights

The adult patient segment captured the largest market share of 42% in 2023.

The growth of the segment is attributed to the rising cases of asthma and chronic obstructive pulmonary disease among the geriatric or adult population aged between 45-65 years. The aging factors and higher adoption of lifestyles like smoking, drinking, faster lifestyle, unhealthy living standards, and rising environmental pollution are driving the cases of lung diseases such as breathlessness, asthma, COPD, and other breathing-related diseases that drive the demand for inhalation and nasal spray generic drugs by the adult patients.

The pediatric patient segment is expected to grow significantly in the market during the forecast period. The increasing cases of lung diseases like asthma, cystic fibrosis, and chronic lung disease in children are driving the demand for inhalation and nasal spray generic drugs to treat such diseases.

Indication Insights

The asthma segment contributed more than 43% of market share in 2023

The rising cases of asthma cases in the population are due to the rising acceptance of sedentary lifestyles and unhealthy eating and sleeping habits that cause several negative impacts on the body. The increasing pollution level and the global warming in the environment from the rising number of vehicles and industrial pollution are some of the leading causes of increasing cases of asthma. This, also called bronchial asthma, affects the lungs.

Asthma causes severe effects on the breathing muscles, such as bronchospasm, inflammation, and mucus production. There are two types of asthma: persistent and intermittent. Environmental factors, allergies, genetics, and respiratory infections are some of the major causes of asthma. There are some types of treatments for asthma that physicians prescribe, such as bronchodilators, anti-inflammatory medicines, and biological therapies for asthma.

The chronic obstructive pulmonary disease (copd) segment is expecting notable growth in the inhalation and nasal spray generic drugs market during the anticipated period. There are increasing cases of COPD in the adult population due to the aging factor, and the major causes of the disease are smoking and air pollution. This disease can be permanently curable, but it can be improved by avoiding smoking and reducing exposure to air pollution.

• As per the WHO data, chronic obstructive pulmonary disease (COPD) is the third major cause of death globally. Smoking is the major factor, with 70% of COPD cases in economically developing and developed countries.
• 90% of Chronic Obstructive Pulmonary Disease (COPD) deaths are under 70 years of age in low- and middle-income countries (LMIC).

End-User Insights

The homecare segment dominated the market with the biggest market share of 53% in 2023 and is expected to sustain its dominance during the forecast period. The rising awareness about health conditions and the advancement in medication products such as inhalers, nasal sprays, and other medications for breathing diseases drive the growth of the market.

The increasing use of inhalers and nasal sprays for the treatment of diseases such as asthma and COPD, the avoidance of unnecessary hassle in the healthcare center, and the increasing trend towards telehealth or telemedicine drive the adoption of the homecare segment. The rising geriatric population is one of the leading factors driving the growth of the homecare segment worldwide.

Distribution Channel Insights

The retail pharmacies segment recorded the highest market share of 57% in 2023. 

The rising acceptance of retail pharmacies for buying any type of medication that is prescribed by the physician due to hassle-free experience and availability of generic drugs are driving the growth of retail pharmacies. The rising surging expenditure on individual healthcare by the people is driving the growth of the market. Retail pharmacies are more approachable than any other drug distribution source, which also drives the growth of the retail pharmacies segment.

The online pharmacies segment is expected to hold a significant share of the inhalation and nasal spray generic drugs market during the forecast period. The rising trend towards the online buying of goods from the population in the home comfort is driving the adoption of online pharmacies. The higher availability of a number of prescribed generic drugs at discounted prices and delivered to the doorstep makes it easy for the geriatric population, contributing to the growth of the online pharmacies segment.

Inhalation and Nasal Spray Generic Drugs Companies

• Apotex Inc.
• Hikma Pharmaceuticals PLC
• Sun Pharmaceuticals Industries Ltd.
• Teva Pharmaceuticals Industries Ltd.
• Mylan N.V.
• Akorn, Operating Company LLC
• Cipla Inc.
• Sandoz International GmBH (Novartis AG)
• Beximco Pharmaceuticals Ltd.
• Nephron Pharmaceuticals Corporation

Recent Development

• In July 2023, Kindeva Drug Delivery L.P. and Viatris Inc., a leading healthcare company, announced the introduction of Breyna™ an Inhalation Aerosol, the first generic version of AstraZeneca's Symbicort® approved by the U.S. Food and Drug Administration (FDA).
• In May 2024, U.S. pharmacy chain operator Walgreens Boots Alliance launched Naloxone, its own popular brand, a popular overdose reversal drug. The launch was introduced in April after the U.S. Food and Drug Administration approved the Walgreens brand.

Segments covered in the Report

By Drug Class

• Bronchodilators
• Combination Drugs
• Corticosteroids
• Decongestant Sprays
• Antihistamines
• Others

By Patient Demographics

• Geriatric Patient
• Adult Patient
• Pediatric Patient

By Indication

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Allergic Rhinitis
• Others

By End-user

• Hospitals
• Homecare
• Others

By Distribution Channel

• Hospitals Pharmacy
• Retail Pharmacy
• Online Pharmacies

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa